Koselugo (Selumetinib Sulfate) Patent Expiration, LOE Window & CMS Spending
Koselugo (Selumetinib Sulfate) by AstraZeneca: FDA Orange Book core substance LOE 2028-03-13 (last listed 2032-11-19), 0 AB generics, $98.2M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N213756 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2028-03-13 |
| Last Listed Patent or Exclusivity Date | 2032-11-19 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $98.2M |
| 2024 Medicare Part D Spend | $22.4M |
| 2024 Medicaid Spend | $75.8M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 20.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.